Development of novel drugs for human African trypanosomiasis

Brun, R., Don, R., Jacobs, R.T., Wang, M.Z. and Barrett, M.P. (2011) Development of novel drugs for human African trypanosomiasis. Future Microbiology, 6(6), pp. 677-691. (doi:10.2217/fmb.11.44)

Full text not currently available from Enlighten.

Publisher's URL: http://dx.doi.org/10.2217/fmb.11.44

Abstract

Human African trypanosomiasis (HAT) or 'sleeping sickness' is a neglected tropical disease caused by the parasite Trypanosoma brucei. Novel models for funding pharmaceutical development against HAT are beginning to yield results. The Drugs for Neglected Diseases initiative (DNDi) rediscovered a nitroimidazole, fexinidazole, which is currently in Phase I clinical trials. Novel benzoxaboroles, discovered by Anacor, Scynexis and DNDi, have good pharmacokinetic properties in plasma and in the brain and are curative in a murine model of stage two HAT with brain infection. The Consortium for Parasitic Drug Development (CPDD) has identified a series of dicationic compounds that can cure a monkey model of stage two HAT. With other screening programs yielding hits, the pipeline for new HAT drugs might finally begin to fill

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Barrett, Professor Michael
Authors: Brun, R., Don, R., Jacobs, R.T., Wang, M.Z., and Barrett, M.P.
College/School:College of Medical Veterinary and Life Sciences > Institute of Infection Immunity and Inflammation
Journal Name:Future Microbiology
ISSN:1746-0913

University Staff: Request a correction | Enlighten Editors: Update this record